Zimmer Biomet Holdings Inc (ZBH) to Post FY2017 Earnings of $8.03 Per Share, Cantor Fitzgerald Forecasts
Zimmer Biomet Holdings Inc (NYSE:ZBH) – Equities research analysts at Cantor Fitzgerald issued their FY2017 earnings estimates for shares of Zimmer Biomet in a report issued on Sunday. Cantor Fitzgerald analyst C. Bijou expects that the medical equipment provider will post earnings per share of $8.03 for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Zimmer Biomet’s FY2018 earnings at $8.15 EPS.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a return on equity of 3.82% and a net margin of 5.43%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.79 earnings per share.
Several other brokerages also recently weighed in on ZBH. Royal Bank of Canada cut their price target on Zimmer Biomet to $125.00 and set an “outperform” rating for the company in a report on Tuesday, November 7th. SunTrust Banks set a $136.00 price target on Zimmer Biomet and gave the company a “buy” rating in a report on Wednesday, November 1st. Morgan Stanley cut their price target on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. BMO Capital Markets cut their price target on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, November 2nd. Finally, Deutsche Bank upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price target for the company in a report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $137.42.
Zimmer Biomet (NYSE ZBH) opened at $122.29 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $24,760.00, a price-to-earnings ratio of 38.10, a price-to-earnings-growth ratio of 1.96 and a beta of 1.15. Zimmer Biomet has a twelve month low of $108.03 and a twelve month high of $133.49.
A number of institutional investors have recently made changes to their positions in ZBH. Bank of Nova Scotia Trust Co. purchased a new stake in Zimmer Biomet during the 3rd quarter worth $112,000. FNY Managed Accounts LLC purchased a new stake in Zimmer Biomet during the 3rd quarter worth $117,000. Steward Partners Investment Advisory LLC purchased a new stake in Zimmer Biomet during the 3rd quarter worth $140,000. BB&T Investment Services Inc. purchased a new stake in Zimmer Biomet during the 2nd quarter worth $144,000. Finally, Sandy Spring Bank boosted its position in Zimmer Biomet by 5.4% during the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 66 shares during the period. 85.92% of the stock is owned by hedge funds and other institutional investors.
The firm also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Investors of record on Friday, December 29th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. Zimmer Biomet’s dividend payout ratio (DPR) is 29.91%.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with Analyst Ratings Network's FREE daily email newsletter.